Page last updated: 2024-11-07

trans-1,2-dihydro-1,2-naphthalenediol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

trans-1,2-dihydro-1,2-naphthalenediol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(1S,2S)-1,2-dihydronaphthalene-1,2-diol : The (1S,2S)-isomer of trans-1,2-dihydronaphthalene-1,2-diol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID114831
CHEBI ID28809
SCHEMBL ID2930945
MeSH IDM0494977

Synonyms (28)

Synonym
CHEBI:28809 ,
(1s,2s)-1,2-dihydroxy-1,2-dihydronaphthalene
C04514
trans-1,2-dihydronaphthalene-1,2-diol
(1s,2s)-1,2-dihydronaphthalene-1,2-diol
trans-1,2-dihydro-1,2-naphthalenediol
dihydrodiol
771-16-4
AKOS006281898
1,2-naphthalenediol, 1,2-dihydro-, (1r,2r)-rel-
s8a9yql2ys ,
1,2-naphthalenediol, 1,2-dihydro-, trans-
unii-s8a9yql2ys
1,2-naphthalenediol, 1,2-dihydro-, (1s-trans)-
1,2-dihydro-1,2-naphthalenediol (1s-trans)-
13011-97-7
1,2-naphthalenediol, 1,2-dihydro-, (1s,2s)-(+)-
(1s,2s)-trans-1,2-dihydro-1,2-naphthalenediol
rac trans-1,2-dihydroxy-1,2-dihydronaphthalene
(1r,2r)-rel-1,2-dihydro-1,2-naphthalenediol
trans-1,2-naphthalenedihydrodiol
(+/-)-trans-1,2-dihydroxy-1,2-dihydronaphthalene
SCHEMBL2930945
(1s,2s)-trans-1,2-dihydro-1,2-naphthalenediol, >=96.0% (hplc)
QPUHWUSUBHNZCG-UWVGGRQHSA-N
DTXSID00926599
Q27103910
1.beta.,2.alpha.-dihydroxy-1,2-dihydronaphthalene

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Finally, the assay was used for a pharmacokinetic study of plasma levels in treated FVB mice."( Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies.
Beijnen, JH; Rood, JJM; Schellens, JHM; Schinkel, AH; Sparidans, RW; van Hoppe, S, 2016
)
0.43
" The aim of this work is to develop a population pharmacokinetic model for ibrutinib and its dihydrodiol metabolite to quantify pharmacokinetic inter- and intra-individual variability, to evaluate the impact of several covariates on ibrutinib pharmacokinetic parameters, and to examine the relationship between exposure and clinical outcome."( Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies.
Allal, B; Chatelut, E; De Barros, S; Despas, F; Dupré, L; Gallais, F; Obéric, L; Protin, C; Quillet-Mary, A; Thomas, F; White-Koning, M; Ysebaert, L, 2020
)
0.56
" Pharmacokinetic blood samples were taken from months 1 to 12 after inclusion."( Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies.
Allal, B; Chatelut, E; De Barros, S; Despas, F; Dupré, L; Gallais, F; Obéric, L; Protin, C; Quillet-Mary, A; Thomas, F; White-Koning, M; Ysebaert, L, 2020
)
0.56
"A total of 89 patients and 1501 plasma concentrations were included in the pharmacokinetic analysis."( Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies.
Allal, B; Chatelut, E; De Barros, S; Despas, F; Dupré, L; Gallais, F; Obéric, L; Protin, C; Quillet-Mary, A; Thomas, F; White-Koning, M; Ysebaert, L, 2020
)
0.56
"We present the first population pharmacokinetic model describing ibrutinib and dihydrodiol-ibrutinib concentrations simultaneously."( Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies.
Allal, B; Chatelut, E; De Barros, S; Despas, F; Dupré, L; Gallais, F; Obéric, L; Protin, C; Quillet-Mary, A; Thomas, F; White-Koning, M; Ysebaert, L, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
" A link between the dosing compartment and the dihydrodiol-ibrutinib central compartment was added to assess for high first-pass hepatic metabolism."( Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies.
Allal, B; Chatelut, E; De Barros, S; Despas, F; Dupré, L; Gallais, F; Obéric, L; Protin, C; Quillet-Mary, A; Thomas, F; White-Koning, M; Ysebaert, L, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
trans-1,2-dihydronaphthalene-1,2-diol
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's12 (41.38)29.6817
2010's8 (27.59)24.3611
2020's9 (31.03)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (3.45%)0.25%
Other27 (93.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]